Over the last 10 to 20 years, the irritable bowel syndrome (IBS) has garnered considerable scientific interest. The acceptance of the biopsychosocial model (1), the application of symptom-based diagnostic criteria (for example, Rome diagnostic criteria), and the growth in biological and behavioral measurement technology (2, 3) has created a fertile area for new research in IBS with the potential for more effective treatments. Research now focuses on altered motility and neuroenteric signaling; visceral hypersensitivity and its enhancement by inflammation and altered mucosal immunity; and brain–gut dysfunction via altered pain, autonomic, and stress-related (for example, corticotropin-releasing hormone) pathways (2, 3). It ...
References
- 1.
Drossman DA . Presidential address: gastrointestinal illness and the biopsychosocial model. Psychosom Med. 1998;60:258-67. [PMID:9625212 ] CrossrefMedlineGoogle Scholar - 2.
Drossman DA . The functional gastrointestinal disorders and the Rome III process.. In: Drossman DA, Corazziari E, Delvaux M, Spiller R, Talley NJ, Thompson WG, et al, eds. Rome III: The Functional Gastrointestinal Disorders. 3rd ed. McLean, VA: Degnon Associates; 2006:1-30. Google Scholar - 3.
Drossman DA . The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130:1377-90. [PMID:16678553 ] CrossrefMedlineGoogle Scholar - 4.
Mearin F ,Pérez-Oliveras M ,Perelló A ,Vinyet J ,Ibañez A ,Coderch J ,et al . Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology. 2005;129:98-104. [PMID:16012939 ] CrossrefMedlineGoogle Scholar - 5.
Dunlop SP ,Jenkins D ,Neal KR ,Spiller RC . Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology. 2003;125:1651-9. [PMID:14724817 ] CrossrefMedlineGoogle Scholar - 6.
Malinen E ,Rinttilä T ,Kajander K ,Mättö J ,Kassinen A ,Krogius L ,et al . Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol. 2005;100:373-82. [PMID:15667495 ] CrossrefMedlineGoogle Scholar - 7.
O'Mahony L ,McCarthy J ,Kelly P ,Hurley G ,Luo F ,Chen K ,et al . Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541-51. [PMID:15765388 ] CrossrefMedlineGoogle Scholar - 8.
Kajander K ,Hatakka K ,Poussa T ,Färkkilä M ,Korpela R . A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther. 2005;22:387-94. [PMID:16128676 ] CrossrefMedlineGoogle Scholar - 9.
Spiller R . Probiotics: an ideal anti-inflammatory treatment for IBS? [Editorial]. Gastroenterology. 2005;128:783-5. [PMID:15765414 ] CrossrefMedlineGoogle Scholar - 10.
Lee HR ,Pimentel M . Bacteria and irritable bowel syndrome: the evidence for small intestinal bacterial overgrowth. Curr Gastroenterol Rep. 2006;8:305-11. [PMID:16836942 ] CrossrefMedlineGoogle Scholar - 11.
Pimentel M ,Chow EJ ,Lin HC . Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412-9. [PMID:12591062 ] MedlineGoogle Scholar - 12.
Pimentel M ,Chow EJ ,Lin HC . Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503-6. [PMID:11151884 ] CrossrefMedlineGoogle Scholar - 13.
Lin HC . Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA. 2004;292:852-8. [PMID:15316000 ] CrossrefMedlineGoogle Scholar - 14.
Pimentel M ,Park S ,Mirocha J ,Kane SV ,Kong Y . The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome. A randomized trial. Ann Intern Med. 2006;145:557-63. LinkGoogle Scholar - 15.
Di Stefano M ,Malservisi S ,Veneto G ,Ferrieri A ,Corazza GR . Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2000;14:551-6. [PMID:10792117 ] CrossrefMedlineGoogle Scholar - 16.
Irvine EJ ,Whitehead WE ,Chey WD ,Matsueda K ,Shaw M ,Talley NJ ,et al . Design of treatment trials for functional gastrointestinal disorders.. In: Drossman DA, Corazziari E, Delvaux M, Spiller R, Talley NJ, Thompson WG, et al, eds. Rome III: The Functional Gastrointestinal Disorders. 3rd ed. McLean, VA: Degnon Associates; 2006:779-834. Google Scholar - 17.
Irvine EJ ,Whitehead WE ,Chey WD ,Matsueda K ,Shaw M ,et al . Design of treatment trials for functional gastrointestinal disorders. Gastroenterology. 2006;130:1538-51. [PMID:16678567 ] CrossrefMedlineGoogle Scholar - 18.
Sharara AI ,Aoun E ,Abdul-Baki H ,Mounzer R ,Sidani S ,Elhajj I . A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101:326-33. [PMID:16454838 ] CrossrefMedlineGoogle Scholar - 19.
Walters B ,Vanner SJ . Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol. 2005;100:1566-70. [PMID:15984983 ] CrossrefMedlineGoogle Scholar - 20. Ruff KC, Saito-Loftus YA, Locke GR, Harmsen WS, Zinsmeister AS, Talley NJ. Failure to detect association with irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO) [Abstract]. Am J Gastroenterol. 2006;101(S2):S488 [Forthcoming]. Google Scholar
- 21.
Riordan SM ,McIver CJ ,Walker BM ,Duncombe VM ,Bolin TD ,Thomas MC . The lactulose breath hydrogen test and small intestinal bacterial overgrowth. Am J Gastroenterol. 1996;91:1795-803. [PMID:8792701 ] MedlineGoogle Scholar - 22.
Corazza GR ,Menozzi MG ,Strocchi A ,Rasciti L ,Vaira D ,Lecchini R ,et al . The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology. 1990;98:302-9. [PMID:2295385 ] CrossrefMedlineGoogle Scholar - 23.
Maxwell PR ,Rink E ,Kumar D ,Mendall MA . Antibiotics increase functional abdominal symptoms. Am J Gastroenterol. 2002;97:104-8. [PMID:11808932 ] CrossrefMedlineGoogle Scholar
Author, Article, and Disclosure Information
Affiliations:
From the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Disclosures: None disclosed.
Corresponding Author: Douglas A. Drossman, MD, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, CB7080, 4150 Bioinformatics Building, Chapel Hill, NC 27599-7080.
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.
*All comments submitted after October 1, 2021 and selected for publication will be published online only.